Paeoniflorin inhibits proliferation and promotes apoptosis of multiple myeloma cells via its effects on microRNA-29b and matrix metalloproteinase-2

SHAOFENG WANG and WENHUA LIU

Department of Orthopedics, The Affiliated Hospital of Weifang Medical College, Weifang, Shandong 261031, P.R. China

Received January 25, 2015; Accepted October 29, 2015

DOI: 10.3892/mmr.2016.5498

Abstract. Multiple myeloma (MM) is a type of cancer characterized by the excessive proliferation of malignant plasma cells. In China, the incidence of MM has been increasing annually. Paeoniflorin exerts numerous functions, including coronary vessel expansion, and anti-inflammation and anticancer activities. The present study aimed to investigate the effects of paeoniflorin on the proliferation and apoptosis of SKO-007 MM cells, via its effects on the regulation of matrix metalloproteinase-2 (MMP-2) and microRNA (miR)-29b. In the present study, an MTT assay was used to analyze the proliferation of SKO-007 cells treated with paeoniflorin. Annexin V-fluorescein isothiocyanate/propidium iodide apoptosis and caspase-3 activation assays were used to detect the levels of cellular apoptosis. The expression levels of MMP-2 and miR-29b were detected using gelatin zymography and quantitative-polymerase chain reaction, respectively. In addition, miR-29b and anti-miR-29b plasmids were transfected into SKO-007 cells, and the effects of paeoniflorin on cell proliferation and apoptosis were subsequently detected. The results of the present in vitro studies demonstrated that paeoniflorin was able to inhibit the proliferation of SKO-007 cells in a dose- and time-dependent manner. Furthermore, paeoniflorin effectively increased cell apoptosis, and augmented the activation of caspase-3 and caspase-9 in the SKO-007 cells. The expression levels of MMP-2 were suppressed following treatment of the SKO-007 cells with paeoniflorin. In addition, paeoniflorin was able to induce the expression of miR-29b. Notably, the results of the present study indicated that miR-29b expression may control the expression of MMP-2 in SKO-007 cells. In conclusion, the present study demonstrated that paeoniflorin was able to inhibit cell proliferation and promote apoptosis of MM cells by suppressing the expression of MMP-2, via the upregulation of miR-29b.

Introduction

Multiple myeloma (MM), which is also known as plasma cell myeloma, is a type of cancer characterized by the excessive proliferation of malignant plasma cells, extensive osteolytic lesions, and/or osteoporosis (1). In recent years, among the hematological malignancies, the incidence of MM in the United States has overtaken acute leukemia, and is second only to non-Hodgkin's lymphoma (2). In addition, the incidence of MM in China has been increasing annually (3). MM is the most common primary tumor of the bone marrow in the USA (4,5).

Matrix metalloproteinases (MMPs), which belong to the zinc-dependent endopeptidase family, exert proteolytic activity and are associated with bone remodeling, bone resorption, tumor invasion and metastasis (6,7). Previous studies have also demonstrated that in myeloma cells, elevated levels of MMP-2 may be associated with disease progression, angiogenesis, and myeloma bone disease (8,9). In addition, Zdziszińska et al (9) reported that suppression of MMP-2 activity was able to inhibit the proliferation of MM cells.

MicroRNAs (miRs) are small (19-25 nucleotides) non-coding RNA molecules that are involved in genetic regulation. miRs are involved in regulating various biological signaling pathways, and have several roles in the regulation of cell growth and development (10). miRs account for 1-2% of the known eukaryotic genome, and have a role in tumor biology, as either tumor suppressor genes or proto-oncogenes (11). Overexpression of miR-29b has previously been shown to reduce the protein expression levels of myeloid cell leukemia 1 (Mcl-1), thereby inhibiting the growth of MM cells. miR-29b has also been reported to inhibit the interleukin-6-induced upregulation of Mcl-1, thus suggesting that miR-29b may act as a tumor suppressor gene (12,13).

Paeoniflorin exerts numerous functions, including sedation, spasmolysis, anti-inflammation, memory improvement, blood glucose-lowering effects, anti-emergency ulcer, coronary vessel expansion, anti-acute ovarian cancer and inhibition of cardiac ischemia and platelet aggregation (14). It has previously been demonstrated that paeoniflorin may effectively modulate the multidrug resistance of the SGC7901 human gastric cancer cell line, via inhibition of nuclear factor-κB activation (15).
Furthermore, paeoniflorin has been reported to significantly induce the apoptosis of HeLa human cervical cancer cells, via the downregulation of B-cell lymphoma-2 (Bcl-2) and the upregulation of caspase-3 (16). However, whether paeoniflorin affects the proliferation and apoptosis of SKO-007 MM cells via suppression of MMP-2 expression and upregulation of miR-29b remains unknown. The present study aimed to investigate the effects and underlying molecular mechanisms of paeoniflorin on MM cell proliferation and apoptosis.

Materials and methods

Reagents and chemicals. The chemical structure of paeoniflorin (Sigma-Aldrich, St. Louis, MO, USA; purity >98%) is presented in Fig. 1. Paeoniflorin was dissolved in physiological saline, according to the manufacturer’s protocol (17). RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Caspase-3/9 Activity Assay kits and Annexin V-Fluorescein Isothiocyanate (FITC)/Propidium Iodide (PI) Apoptosis Detection kit were purchased from Nanjing KeyGen Biotech Co., Ltd. (Nanjing, China). TRIzol reagent and quantitative-polymerase chain reaction (qPCR) assays were purchased from Invitrogen (Thermo Fisher Scientific, Inc.).

Cell culture. The SKO-007 human MM cell line (Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China) was cultured in RPMI-1640 medium supplemented with 10% FBS, 100 units/ml penicillin and 100 mg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C in a humidified atmosphere containing 5% CO₂. The culture media were changed every 2-3 days.

Cell viability assay. SKO-007 cells were seeded at a density of 1x10⁵/well into 96-well plates, and were treated with paeoniflorin (0, 5, 10 and 20 µM) for 48 h. Next, GM60001 (5 µM) was used to suppress the expression of MMP-2 and added to SKO-007 cells for 48 h. Subsequently, cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Beyotime Institute of Biotechnology, Jiangsu, China) assay. Briefly, 15 µl MTT was added to each well and incubated for 4 h at 37°C in a humidified atmosphere containing 5% CO₂. The culture media were changed every 2-3 days.

Caspase-3 and caspase-9 activation assay. SKO-007 cells were seeded at a density of 1x10⁵/well into 96-well plates, and were treated with paeoniflorin (0, 5, 10 and 20 µM) for 48 h. Caspase-3 and caspase-9 activities were measured using Caspase-3/9 Activity Assay kits, according to the manufacturer’s protocol. Briefly, 10 µl protein cell lysate (containing 50mM Tris-HCl pH8.0, 5mM EDTA, 150mM NaCl, 1% Triton-X 100; Beyotime Institute of Biotechnology) per sample was added to 100 µl reaction buffer containing 10 µl substrate (Ac-DEVD-pNA for caspase-3, and Ac-LEHD-pNA for caspase-9) and incubated at 37°C for 4-6 h. Caspase-3 and caspase-9 activities were measured at an absorbance of 405 nm.

Gelatin zymography. SKO-007 cells were seeded at a density of 1x10⁵/well into 6-well plates, and were treated with paeoniflorin (0, 5, 10 and 20 µM) for 48 h. The expression levels of MMP-2 in the SKO-007 cells were determined using zymographic analysis. Briefly, every sample was subjected to 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis containing 0.1% gelatin. Following electrophoresis, the gels were washed with 50 mM Tris-HCl (pH 7.6) three times for 30 min at room temperature, in order to remove the SDS. The gels were then incubated in a reaction buffer (Beyotime Institute of Biotechnology) for 12 h at 37°C, after which, the gel was stained with 0.1% Coomassie Brilliant Blue G250 (Aladdin Industrial Corporation, Shanghai, China) for 1 h and destained in 10% acetic acid and 10% methanol. The resulting gels were analyzed using a film processor (CP1000; Agfa-Gevaert NV, Mortsel, Belgium).

Reverse transcription-qPCR analysis of miR-29b expression. SKO-007 cells were seeded at a density of 1x10⁵/well into 6-well plates, and were treated with paeoniflorin (0, 5, 10 and
paeoniflorin (10 µM) for 48 h. Total RNA was extracted from the cells using TRIzol reagent, and miRs were specifically amplified for quantification using individual miRNA TaqMan Real-Time qPCR analysis (Invitrogen; Thermo Fisher Scientific, Inc.). The primer sequences were as follows: miR-29b, forward 5'-GGGGTACCTTCAAGTGGTTTCT-3' and reverse 5'-GGGGATATCTACGTGAGGCAAGTCTTCAC-3'; and U6, forward 5'-CGCTTCCGCACAGCATATACTA-3' and reverse 5'-CGCTTACGAATTTCGTGTC-3'. The PCR conditions were 95°C for 60 sec, 95°C for 30 sec, 60°C for 45 sec, 72°C for 30 min, 55°C for 30 sec, for 35 cycles. The results were normalized to β-actin. ΔCq was calculated by subtracting the Ct of U6. The ΔΔCq was then calculated by subtracting the ΔCq of the negative control from the ΔCq of the samples using the 2−ΔΔCq method (18).

Transfection of miR-29b and anti-miR-29b plasmids. miR-29b and anti-miR-29b plasmids and their negative controls were designed and synthesized by Sangon Biotech Co., Ltd. (Shanghai, China). Sequences for miR-29b plasmid 5'-GGG GGTACCTTCAAGTGGTTTCT-3' and 5'-GGGGATATCTACGTGAGGCAAGTCTTCAC-3' and anti-miR-29b plasmid 5'-ACTGATTTCAATGGTGCTT-3' and 5'-GTGTAACAGTCTACGGCCA-3'. Once the SKO-007 cells, which were seeded into 6-well plates (1x10⁴ cells/well), had reached 50-60% confluence, the plasmids were transfected into the cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol.

Statistical analysis. All experiments were repeated three times, in order to ensure reproducibility. The data are presented as the mean ± standard deviation, and were analyzed using SPSS 18 (SPSS Inc., Chicago, IL, USA). Comparisons between mean values were tested using Student's unpaired t-test. *P<0.05 was considered to indicate a statistically significant difference.

Results

Paeoniflorin inhibits the proliferation of SKO-007 cells. The effects of paeoniflorin were examined on the proliferation of the SKO-007 human MM cell line. Treatment with paeoniflorin inhibited the proliferation of SKO-007 cell in a dose- and time-dependent manner (Fig. 2). When the cells were treated with 5 µM paeoniflorin for 72 h, 10 µM paeoniflorin for 48 or 72 h, or 20 µM paeoniflorin for 24, 48 or 72 h, cell proliferation was significantly reduced, as compared with the untreated cells (Fig. 2).

Paeoniflorin exerts cell cytotoxic effects on SKO-007 cells. To determine whether paeoniflorin was cytotoxic to SKO-007 cells, an LDH assay was conducted following treatment with paeoniflorin (0, 5, 10 and 20 µM) for 48 h. As indicated in Fig. 3, paeoniflorin exerted cell cytotoxic effects on SKO-007 cells in a dose-dependent manner. The cell cytotoxic effects of paeoniflorin on SKO-007 cells markedly increased following treatment with 10 or 20 µM paeoniflorin for 48 h (Fig. 3).

Paeoniflorin induces apoptosis of SKO-007 cells. To investigate whether paeoniflorin was able to promote SKO-007 cell apoptosis, the number of apoptotic cells was determined using an Annexin V-FITC/PI apoptosis assay. Treatment with paeoniflorin (0, 5, 10 and 20 µM) for 48 h induced a concentration-dependent increase in the rate of SKO-007 cell apoptosis (Fig. 4A and B). Following treatment with 10 or 20 µM paeoniflorin, the number of SKO-007 apoptotic cells was significantly increased (Fig. 4A and B).

Paeoniflorin induces caspase-3 and caspase-9 activities in SKO-007 cells. To further investigate the effects of paeoniflorin on the caspase activity of SKO-007 cells, caspase-3 and caspase-9 activities were measured using Caspase-3/9 Activity Assay kits. Notably, treatment with paeoniflorin (10 and 20 µM) for 48 h induced caspase-3 and caspase-9 activities in SKO-007 cells (Fig. 5A and B).

Paeoniflorin inhibits MMP-2 protein expression levels in SKO-007 cells. The present study aimed to determine whether paeoniflorin was able to inhibit the expression levels of MMP-2 in SKO-007 cells. Treatment with paeoniflorin (10 and 20 µM) for 48 h markedly inhibited the protein expression levels of MMP-2 in the SKO-007 cells (Fig. 6A and B).

Suppression of MMP-2 reduces the proliferation of paeoniflorin-treated SKO-007 cells. To determine the potential regulatory mechanisms underlying the effects of paeoniflorin (10 µM) on the proliferation of SKO-007 cells after 48 h, the cells were treated with an MMP-2 inhibitor, GM6001 (5 µM; Chemicon International, Temecula, CA,
USA). Treatment of the cells with the MMP-2 inhibitor suppressed the protein expression levels of MMP-2, and further reduced the proliferation of paeoniflorin-treated cells (Fig. 7A-C).

**Paeoniflorin upregulates miR-29b expression in SKO-007 cells.** The present study aimed to investigate whether paeoniflorin was able to activate miR-29b expression in SKO-007 cells. Following treatment with paeoniflorin (10 and 20 µM) for 48 h, the expression levels of miR-29b were significantly increased in the SKO-007 cells (Fig. 8).

**Overexpression of miR-29b inhibits MMP-2 expression in SKO-007 cells.** SKO-007 cells were transfected with miR-29b, in order to determine whether overexpression of miR-29b was able to inhibit the expression of MMP-2. Transfection of the cells with miR-29b increased the expression levels of miR-29b and suppressed the expression of MMP-2 in SKO-007 cells (Fig. 9A and B).

**Anti-miR-29b attenuates the effects of paeoniflorin.** To determine whether a correlation exists between the effects of paeoniflorin and miR-29b expression, the effects of paeoniflorin on SKO-007 cells transfected with anti-miR-29b were investigated. Transfection with an anti-miR-29b antibody significantly reduced the expression levels of miR-29b in SKO-007 cells (Fig. 10A). Notably, transfection with anti-miR-29b significantly attenuated the effects of paeoniflorin on cell proliferation (Fig. 10B) and apoptosis (Fig. 10C) in SKO-007 cells. Furthermore, transfection with anti-miR-29b was able to upregulate the expression levels of MMP-2 in SKO-007 cells (Fig. 10D).
Discussion

MM is a debilitating and incurable malignant disease, which originates in B cells. MM is characterized by the malignant proliferation and abnormal accumulation of bone marrow clonal plasma cells, and is associated with increased monoclonal immunoglobulin levels (19,20). In the present study, treatment with paeoniflorin was able to inhibit the proliferation of SKO-007 cells in a dose- and time-dependent manner. Paeoniflorin is a promising agent in the treatment of liver cancer via the downregulation of prostaglandin E2 receptor 2 expression and the increased activation of caspase-3 (21). In addition, in the present study paeoniflorin significantly enhanced cell cytotoxicity, increased apoptosis, and accelerated caspase-3 activation in SKO-007 cells. Zhang and Zhang (17) reported that paeoniflorin was able to significantly induce the apoptosis of HeLa cells, via the downregulation of Bcl-2 and the upregulation of caspase-3 (22). Hung et al (23) demonstrated that the antiproliferative activity of paeoniflorin promoted the apoptosis of A549 human non-small cell lung cancer cells.

Figure 6. Paeoniflorin inhibited the protein expression levels of MMP-2 in the SKO-007 human multiple myeloma cells. The effects of paeoniflorin on (A) MMP-2 expression. (B) Statistical analysis of MMP-2 protein expression levels. Data are presented as the mean ± standard deviation. *P<0.01, compared with the 0 µM paeoniflorin treatment group. MMP-2, matrix metalloproteinase-2.

Figure 7. MMP-2 suppression further reduced the proliferation of paeoniflorin-treated SKO-007 human multiple myeloma cells. Treatment with the MMP-2 inhibitor (A) inhibited MMP-2 expression. (B) statistical analysis of MMP-2 protein expression; and (C) further reduced the proliferation of paeoniflorin-treated cells. Data are presented as the mean ± standard deviation. *P<0.01, compared with the 0 µM paeoniflorin treatment group; #P<0.01, compared with the 10 µM paeoniflorin treatment group. MMP-2, matrix metalloproteinase-2; Pac, paeoniflorin.

Figure 8. Paeoniflorin upregulated miR-29b expression in SKO-007 human multiple myeloma cells. Data are presented as the mean ± standard deviation. *P<0.01, vs. the 0 µM paeoniflorin treatment group; miR-29b, microRNA-29b.
However, further research regarding the underlying molecular mechanisms of paeoniflorin on MM cell proliferation and apoptosis is required.

MMP-2 is usually located in the cytoplasm of tumor cells, and is often detected in the endothelial cells of the vascular basement membrane, thus suggesting that during the invasion of astrocytoma, MMP-2 and vascular endothelial growth factor have a synergistic role in regulating the angiogenesis of tumor vessels in MM (24, 25). The structure of newly formed tumor vasculature is incomplete, and easily leaks, thus affecting the integrity of the blood-brain barrier (BBB); plasma and other macromolecules may penetrate into the cells through the damaged BBB and gather around the tumor, forming extensive peritumoral edema (26). Furthermore, MMP-2 may directly degrade the extracellular matrix of the basement membrane of blood vessels, loosening the structure, which is conducive to the invasion of tumor cells along the basement membrane (27). The results of the present study revealed that paeoniflorin was able to inhibit the expression levels of MMP-2 in SKO-007 cells. In addition, downregulation of MMP-2 further reduced the proliferation of paeoniflorin-treated SKO-007 cells. A previous study demonstrated that paeoniflorin inhibits the MMP-2 activity of splenocytes from picryl chloride-induced ear contact sensitivity mice (28).

In MM, tumor cells proliferate in the surrounding bone marrow, promoting the activities and inhibiting the function of osteoclasts. In experiments on peripheral blood samples, the expression of miR-29b is decreased during osteoclast differentiation, and is therefore considered a negative regulator
of human osteoclast differentiation and activity (29). Furthermore, miR-29b inhibits the activity of tartrate-resistant acid phosphatase on osteoclasts and affects osteoclast induced bone resorption through reducing MMP-9 expression (30,31). The present study demonstrated that paeoniflorin significantly increased the expression levels of miR-29b in SKO-007 cells. Simultaneously, overexpression of miR-29b was capable of inhibiting the expression of MMP-2 in SKO-007 cells. These results indicated that the expression of miR-29b may regulate and control MMP-2 expression in SKO-007 cells; therefore, the miR-29b/MMP-2 signaling pathway may be considered a novel pharmacological target for the treatment of MM using paeoniflorin.

In conclusion, the key observation of the present study was that paeoniflorin was able to inhibit proliferation and promote apoptosis of MM cells via inhibition of MMP-2 and upregulation of miR-29b. Understanding the precise role of paeoniflorin may advance knowledge regarding MM, and may be beneficial for future treatment.

References